Semaglutide Patent Dispute: Delhi Excessive Court docket has issued an vital interim order within the patent dispute associated to Denmark’s drug firm Novo Nordisk’s well-known anti-dibitic and anti-obesity drug semaglutide. Court docket did Dr. Reddy’s Laboratories and Onesource Specialty Pharma have been stopped from gross sales and advertising of this drug in India. Nonetheless, they’re allowed to export their drug into international locations the place the patent of Novo Nordisk shouldn’t be relevant. Semaglutide is offered internationally with ozempic and Wegovy model names. It’s thought-about revolutionary within the remedy of type-2 diabetes and weight problems. Their gross sales have elevated quickly within the world market throughout the previous couple of years. In keeping with the order handed on Might 29 within the courtroom of Nyayaam Amit Bansal, the 2 Indian corporations have assured that they won’t promote medicine in India till the following listening to on 19 August 2025. The courtroom additionally took the plea of the petitioner Novo Nordisk on document that the export of a product with patented violation below Indian legislation additionally falls below the class of violation. The involved information is what the whole patent dispute arose when Dr. Reddy’s began development of semaglutide from April 2025 on the idea of license obtained in December 2024, whereas it has not but obtained a license for its sale in India. The corporate is planning to export this drug to international locations the place there isn’t a validity of patents. Reddy’s stated in a press release to Moneycontrol that the corporate has full potential to construct the generic model of Semaglutide and is making ready to launch it in India and different markets from 2026. The corporate hopes that this drug will play an vital position in its income progress from FY27. It’s engaged in manufacturing the generic model of semaglutide together with different pharma corporations. In the meantime, Novo Nordisk has confirmed that it’ll launch Semaglutide below the Wegovy model in India over the following few weeks. The corporate had tried to launch its drug within the Indian market earlier, however as a result of hurdle of world demand and manufacturing, it needed to postpone its choice. The rising market of medication decreasing medicine is increasing quickly. In keeping with PHARMATRAC knowledge, the market was ₹ 133 crore by March 2022, which elevated to ₹ 576 crore in a number of years – ie a leap of about 4 instances. Behind this speedy enhance, Semaglutide has a giant position, which has a market share alone ₹ 397 crore. That is a lot increased than its different rivals comparable to liraglutide and dulaglutide.
